home / stock / aavxf / aavxf quote
Last: | $15.15 |
---|---|
Change Percent: | 0.99% |
Open: | $15 |
Close: | $15.15 |
High: | $15.15 |
Low: | $15 |
Volume: | 2,000 |
Last Trade Date Time: | 04/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$15.15 | $15 | $15.15 | $15.15 | $15 | 2,000 | 04-22-2024 |
$10.95 | $0 | $10.95 | $0 | $0 | 80 | 04-10-2024 |
$10.95 | $0 | $10.95 | $0 | $0 | 96 | 02-27-2024 |
$10.95 | $0 | $10.95 | $0 | $0 | 25 | 02-20-2024 |
$10.95 | $0 | $10.95 | $0 | $0 | 32,000 | 01-22-2024 |
$10.95 | $10.95 | $10.95 | $10.95 | $10.95 | 1,000 | 01-19-2024 |
$10.5 | $10.5 | $10.5 | $10.5 | $10.5 | 200 | 01-10-2024 |
$10.19 | $10.19 | $10.19 | $10.19 | $10.19 | 207 | 12-12-2023 |
$12.36 | $0 | $12.36 | $0 | $0 | 1,000 | 10-20-2023 |
$12.36 | $12.36 | $12.36 | $12.36 | $12.36 | 1,000 | 10-19-2023 |
$12.3 | $12.3 | $12.3 | $12.7875 | $12.3 | 3,185 | 10-18-2023 |
$18.21 | $0 | $18.21 | $0 | $0 | 10,000 | 09-22-2023 |
$18.21 | $0 | $18.21 | $0 | $0 | 75 | 09-11-2023 |
$18.21 | $18.21 | $18.21 | $18.21 | $18.21 | 5,300 | 09-08-2023 |
$20 | $0 | $20 | $0 | $0 | 50 | 08-29-2023 |
$20 | $0 | $20 | $0 | $0 | 1,067 | 08-23-2023 |
$20 | $0 | $20 | $0 | $0 | 790 | 08-18-2023 |
$20 | $0 | $20 | $0 | $0 | 780 | 08-16-2023 |
$20 | $20 | $20 | $20 | $20 | 200 | 07-27-2023 |
$16.5 | $16.5 | $16.5 | $16.5 | $16.5 | 1,000 | 06-12-2023 |
News, Short Squeeze, Breakout and More Instantly...
Abivax SA Company Name:
AAVXF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...
PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in p...
PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patie...